Periodically, the Health Resources and Services Administration (HRSA) publishes abstracts of information collection requests under review by the Office of Management and Budget (OMB), in compliance with the Paperwork Reduction Act of 1995 (44 U.S.C. Chapter 35). To request a copy of the clearance requests submitted to OMB for review, e-mail email@example.com or call the HRSA Reports Clearance Office on (301) 443-1129.
The following request has been submitted to the Office of Management and Budget for review under the Paperwork Reduction Act of 1995:
Proposed Project: Sickle Cell Disease Program Evaluations and Quality Improvement Activities—[NEW]
The Sickle Cell Disease and Newborn Screening Program (SCDNBSP) and the Sickle Cell Disease Treatment Demonstration Program (SCDTDP) are both administered by the Genetic Services Branch (GSB) of the Division of Services for Children with Special Health Needs in the Health Resources and Services Administration's (HRSA) Maternal and Child Health Bureau (MCHB). The SCDTDP is comprised of geographically distributed regional networks that provide coordinated, comprehensive, culturally competent, and family-centered care to families with sickle cell disease and a national coordinating center to support grantee activities. The SCDTDP is designed to improve access to services for individuals with sickle cell disease, improve/expand patient and provider education, and improve/expand the continuity and coordination of service delivery for individuals with sickle cell disease and carriers of the sickle cell gene mutation. The SCDNBSP is comprised of several national funded community-based sickle cell disease networks located in the U.S. and the National Coordinating and Evaluation Center. The community-based sickle cell disease networks partner with State newborn screening programs, comprehensive sickle cell treatment centers, and health care professionals to provide support to infants screened positive for sickle cell disease, carriers of the sickle cell gene mutation and their families.
HRSA seeks to conduct two evaluations (SCDTDP evaluation previously approved by OMB) and a quality improvement project, the purpose of which are to assess the service delivery processes and outcomes resulting from the systems of care delivered by the SCDNBSP and SCDTDP networks to individuals affected by sickle cell disease who present at their sites for care. The clients of the three programs will be the respondents for this data collection activity.
The annual estimate of burden for both the SCDNBSP and the SCDTDP evaluations and quality improvement effort is as follows:
|Questionnaires||Number of respondents||Responses per respondent||Total responses||Average hours per response||Total hour burden||Wage rate||Total hour cost|
|MDP SCD Questionnaire||140||2||280||.45||126||$20.90||$2633.4|
|MDP SCT Questionnaire||1400||1||1400||.30||420||20.90||8778|
|Utilization Questionnaire (pre-demonstration)||900||1||900||.75||675||20.90||14,107.5|
|Start Printed Page 20994|
|Utilization Questionnaire (post demonstration)||900||1||900||.50||450||20.90||9,405|
|SF-36 Health Survey for adults over 18 years of age||630||2||1260||.25||315||20.90||6,583.5|
|PedsQL for parents of children & adolescents 18 years or younger||270||2||540||.25||135||20.90||2,821.5|
|PedsQL for children & adolescents 18 years or younger||225||2||450||.25||112.5||20.90||2,351.25|
|The Medical Home Family Index (Health Care Satisfaction)||900||2||1800||.25||450||20.90||9,405|
|Hemoglobinopathies Emerging Populations Form (Client Family Communication)||900||2||1800||.20||360||20.90||7,524|
Written comments and recommendations concerning the proposed information collection should be sent within 30 days of this notice to the desk officer for HRSA, either by e-mail to OIRA_submission@omb.eop.gov or by fax to 202-395-6974. Please direct all correspondence to the “attention of the desk officer for HRSA.”Start Signature
Dated: April 8, 2011.
Acting Director, Division of Policy and Information Coordination.
[FR Doc. 2011-9077 Filed 4-13-11; 8:45 am]
BILLING CODE 4165-15-P